glimepiride has been researched along with diazoxide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bijlstra, PJ; Lutterman, JA; Russel, FG; Smits, P; Thien, T | 1 |
| Baxter, GF; Lawrence, CL; Maddock, HL; Mocanu, MM; Standen, NB; Yellon, DM | 1 |
| Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ | 1 |
| Auclair, J; Bouskela, E; Félétou, M; Levens, N; Néliat, G; Ravel, D | 1 |
| Arbeláez, AM; Cryer, PE; Ramanathan, RP | 1 |
| Hamada, Y; Harada, N; Hayashi, Y; Iida, A; Inagaki, N; Ishikawa, K; Izumoto, T; Miki, T; Ogata, H; Oiso, Y; Ozaki, N; Seino, S; Seino, Y; Suzuki, K; Tsunekawa, S; Uenishi, E | 1 |
| Broichhagen, J; Bugliani, M; Frank, JA; Hodson, DJ; Johnston, NR; Marchetti, P; Mitchell, RK; Rutter, GA; Šmid, K; Trauner, D | 1 |
1 review(s) available for glimepiride and diazoxide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for glimepiride and diazoxide
| Article | Year |
|---|---|
Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Topics: Adult; Analysis of Variance; Blood Pressure; Diazoxide; Forearm; Glyburide; Humans; Hypoglycemic Agents; Injections, Intra-Arterial; Male; Muscle, Smooth, Vascular; Nitroprusside; Potassium Channels; Reference Values; Regional Blood Flow; Sulfonylurea Compounds; Vasodilation; Vasodilator Agents | 1996 |
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Dipyridamole; Double-Blind Method; Female; Forearm; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Vasodilation | 2002 |
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.
Topics: Adult; Blood Glucose; C-Peptide; Diazoxide; Female; Glucagon; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; KATP Channels; Male; Sulfonylurea Compounds; Young Adult | 2011 |
10 other study(ies) available for glimepiride and diazoxide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
Topics: Animals; Diazoxide; Glyburide; Guanosine Triphosphate; Heart; Heart Ventricles; Hemodynamics; Hypoglycemic Agents; In Vitro Techniques; Intracellular Membranes; Ischemic Preconditioning, Myocardial; Male; Membrane Potentials; Membrane Proteins; Mitochondria, Heart; Myocardial Infarction; Myocardial Ischemia; Patch-Clamp Techniques; Potassium Channels; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds; Ventricular Function | 2001 |
Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers.
Topics: Adenosine Triphosphate; Animals; Aorta, Thoracic; Cricetinae; Cromakalim; Diazoxide; Drug Interactions; Gliclazide; Glyburide; Guinea Pigs; Hypoglycemic Agents; In Vitro Techniques; Ion Channel Gating; Male; Potassium Channels; Rats; Rats, Wistar; Species Specificity; Sulfonylurea Compounds; Vasodilation; Vasodilator Agents | 2003 |
KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state.
Topics: Animals; Diabetes Mellitus, Experimental; Diazoxide; Gastric Inhibitory Polypeptide; Glucose; KATP Channels; Mice; Phlorhizin; Potassium Channels, Inwardly Rectifying; Sodium-Glucose Transporter 1; Sulfonylurea Compounds | 2014 |
A red-shifted photochromic sulfonylurea for the remote control of pancreatic beta cell function.
Topics: Animals; Azo Compounds; Calcium; Cells, Cultured; Diazoxide; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Light; Mice; Photochemical Processes; Potassium; Signal Transduction; Sulfonylurea Compounds; Sulfonylurea Receptors | 2015 |